This is a working overview of immunomodulator, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Documentaries are informative at times, and certain types are often used within schools as a resource to teach various principles. Documentary filmmakers have a responsibility to be truthful to their vision of the world without intentionally misrepresenting a topic. Social media organizations, such as Dailymotion and YouTube, with many of these platforms receiving popular interest, have provided an avenue for the growth of documentaries as a particular film genre. Such platforms have increased the distribution area and ease of accessibility, given the ability of online video sharing to spread to multiple audiences at once as well as to work past certain socio-political hurdles such as censorship.
=== Isomerisation === In dilute sodium hydroxide or other dilute bases, the monosaccharides mannose, glucose, and fructose interconvert (via a Lobry de Bruyn–Alberda–Van Ekenstein transformation), so that a balance between these isomers is formed. This reaction proceeds via an enediol:
== Personal life == Samberg is married to musician Joanna Newsom. He described himself as her "superfan", and they met at one of her concerts in 2006. After five years of dating, Samberg proposed to her in February 2013, and they married on September 21, 2013, in Big Sur, California, with Saturday Night Live co-star Seth Meyers serving as Samberg's groomsman. In March 2014, Samberg and Newsom purchased the Moorcrest estate in the Beachwood Canyon area of Los Angeles, California, which was associated with various historical figures: in the 1920s, it was owned by the parents of actress Mary Astor; prior to that, Charlie Chaplin rented it. The couple also owns a home in Manhattan's West Village. They announced the birth of their daughter on August 8, 2017. The birth of their second child, a son, was announced by the Lonely Island's Jorma Taccone in February 2023. Samberg, who grew up in the East Bay, is a fan of the Oakland Athletics and the Golden State Warriors. Samberg was raised in a Jewish family, but considers himself "not particularly religious".
Doillon has been drawing since she was 10 and has often included her drawings in her other crafts (the vinyl edition of her album in 2016 and most of her merchandise on tour is drawn by her). She has been keeping a drawn and written diary since the age of 12. She works with an extra fine Sailor Pen on Sennelier paper or Moleskine diaries. In September 2017, Doillon released a book, including 80 ink and pencil drawings alongside diary drawings, with Astier de Villatte. The release was followed by an exhibit of the original drawings at La maison Molière in Paris. She has also, for the brand Astier de Villatte, collaborated on a project of 18 different types of hand-backed ceramic mugs and 15 unique pieces, presented and sold in Tokyo during the launch of the collaboration in November 2017 with creative duo Benoit Astier de Villatte and Ivan Pericoli.
Sources: en.wikipedia.org
=== Criminal justice and "harsh" penalties === As of 2023, 35 countries have the death penalty for drug offenses; of those, the 33 UN full member countries are parties to the UN drug conventions. Nine of those countries – China, Indonesia, Iran, Kuwait, Malaysia, North Korea, Saudi Arabia, Singapore, Vietnam – are considered "high application" countries that regularly perform drug crime executions. The conventions encourage criminal penalties but do not provide guidelines for what is appropriate, which can be "an invitation to governments to enact abusive laws and policies, especially in a global context where drugs and drug trafficking are defined as an existential threat to society and the stability of nations".
Nicotiana tabacum, or cultivated tobacco, is an annually grown herbaceous plant of the genus Nicotiana. N. tabacum is the most commonly grown species in the genus Nicotiana, as the plant's leaves are commercially harvested to be processed into tobacco for human use. The plant is native to Bolivia, commonly grown throughout the world and often found in cultivation. It grows to heights between 1 and 2 metres (3.3 and 6.6 ft). Research is ongoing into its ancestry among wild Nicotiana species, but it is believed to be a hybrid of Nicotiana sylvestris, N. tomentosiformis, and possibly N. otophora.
Big Brown – 2008 Kentucky Derby and Preakness Stakes winner; named after the company Human Intervention Motivation Study MaxiCode – A UPS developed and utilized square barcode-like symbol that appears on their package label
Hoffman alleged Edwards employed monopoly practices in breach of the Sherman Act because it had 70% share of the integrated vacuum pump frame systems market in the US and suppressed competition, imposing non-compete covenants on its suppliers and engaged in employee intimidation; customer threats, and bad faith litigation. In May 2021, Edwards was granted a partial, interim injunction against Hoffman selling a bellows component. Judgement declined to accept Edwards' application of Noerr–Pennington doctrine to dismiss Hoffman's anti competition counterclaim. In June 2022, the parties entered into a Confidential Settlement Agreement through which both parties' claims were dismissed with prejudice.
== References == Atmore, Anthony; Sanders, Peter (1971). "Sotho Arms and Ammunition in the Nineteenth Century". The Journal of African History. 12 (4): 535–544. doi:10.1017/S0021853700011130. ISSN 0021-8537. JSTOR 181011. S2CID 161528484. Bradlow, Edna (1970). "General Gordon in Basutoland". Historia. 15 (4): 223–242. ISSN 0018-229X. Retrieved 7 November 2021. Burman, Sandra (1981). Chiefdom Politics and Alien Law: Basutoland under Cape Rule 1871–1884. Palgrave Macmillan. ISBN 978-1-349-04639-3. Eldredge, Elizabeth (2007). Power in Colonial Africa: Conflict and Discourse in Lesotho, 1870–1960. The University of Wisconsin Press. ISBN 978-0-299-22370-0. Kotze, J. (2012). "Counter-Insurgency in the Cape Colony, 1872–1882". Scientia Militaria: South African Journal of Military Studies. 31 (2): 36–58. doi:10.5787/31-2-152. Retrieved 7 November 2021. Machobane, L. B.; Karschay, Stephan (1990). Government and Change in Lesotho, 1800–1966: A Study of Political Institutions. Palgrave Macmillan. ISBN 978-0-333-51570-9. Maliehe, Sean (2014). "An obscured narrative in the political economy of colonial commerce in Lesotho, 1870–1966". Historia. 59 (2): 28–45. hdl:2263/43121. ISSN 0018-229X. Retrieved 7 November 2021. Rosenberg, Scott; Weisfelder, Richard; Frisbie-Fulton, Michelle (2004). Historical Dictionary of Lesotho. The Scarecrow Press. ISBN 0-8108-4871-6. Tylden, G. (1936). "The Basutoland Rebellion of 1880–1881". Journal of the Society for Army Historical Research. 15 (58): 98–107. ISSN 0037-9700. JSTOR 44227993.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.